In agreement with our results, two published reports have shown that in advanced, refractory prostate cancer, both docetaxel and paclitaxel improve survival, reduce pain, and decrease expression of AR levels and PSA expression (6, 39) , although with significant side effect (40). The gene discussed is KLK3; the disease is prostate cancer.